A pharmaceutical tablet hanging from a chain slams into a cancer cell that's also hanging from a chain, destroying it, illustrating effective pharmaceutical treatments for cancer

iStock, wildpixel

Outside-In Signaling Shows a Route Into Cancer Cells

New study shows how an anticancer drug triggers a signal that gets it sucked into a cancer cell

Updated | 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism that could be exploited for delivering other drugs.

Many malignant cancers overexpress a protein called P-cadherin, which is embedded in the cell membrane.

Lab manager academy logo

Get training in Lab Crisis Preparation and earn CEUs.

One of over 25 IACET-accredited courses in the Academy.

Certification logo

Lab Crisis Preparation course

Because cancer cells have a lot of P-cadherin sticking out of their surface, the protein has been targeted for drug development.

Monoclonal antibodies against P-cadherin can carry a drug payload to the cancer cells.

It has not been clear, though, exactly how the antibodies attach to P-cadherin or how they get inside the cancer cell once attached.

Bin Xie and Shipeng Xu, graduate students in biophysics and biomedical engineering at the University of California, Davis, with Professor Sanjeevi Sivasankar, carried out a series of experiments to study binding of antibody CQY684 to P-cadherin in detail.

P-cadherin is embedded in the cell membrane as a dimer, or matched pair, with P-cadherin on the surface of an adjacent cell.

Interested in life sciences?

Subscribe to our free Life Sciences Newsletter.

Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.

This dimer can exist in two conformations: a more open, "strand-swap" dimer and a cross-shaped, X-dimer.

The researchers found that when the anti-cancer antibody binds to P-cadherin, it locks it into the X-dimer form.

The stable X-form then triggers a chemical signal that causes that patch of membrane to be pinched off and sucked into the cell as a tiny bubble.

The whole P-cadherin/antibody/drug complex is then sent to a structure called the lysosome to be broken down.

"Our results establish an outside-in signaling mechanism that provides fundamental insights into how cells regulate adhesion," the authors wrote. Understanding the binding targets for antibodies against cadherin could help design drugs that exploit this pathway to find and destroy cancer cells.

-Note: This news release was originally published by the University of California - Davis. As it has been republished, it may deviate from our style guide.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - January/February 2025

Energizing Leadership in Action

The science-backed behaviors that help leaders inspire thriving teams and organizations

Lab Manager January/February 2025 Cover Image